Stock analysts at Chardan Capital started coverage on shares of Intellia Therapeutics Inc (NASDAQ:NTLA) in a research report issued to clients and investors on Monday. The firm set a “buy” rating on the stock. The analysts noted that the move was a valuation call.
NTLA has been the topic of a number of other reports. Zacks Investment Research upgraded shares of Intellia Therapeutics from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a report on Wednesday, March 8th. Jefferies Group LLC restated a “buy” rating and set a $33.00 target price on shares of Intellia Therapeutics in a report on Wednesday, February 8th. Wedbush reiterated an “outperform” rating and issued a $25.00 price objective on shares of Intellia Therapeutics in a report on Tuesday, March 14th. Finally, Leerink Swann reiterated an “outperform” rating on shares of Intellia Therapeutics in a report on Thursday, January 5th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $28.83.
Intellia Therapeutics (NASDAQ:NTLA) traded up 0.84% during trading on Monday, hitting $13.18. 241,837 shares of the stock were exchanged. The firm has a 50-day moving average of $13.50 and a 200-day moving average of $14.89. Intellia Therapeutics has a 52 week low of $10.83 and a 52 week high of $30.40. The stock’s market capitalization is $474.77 million.
Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Tuesday, March 14th. The company reported ($0.31) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.21) by $0.10. The company had revenue of $5.63 million for the quarter, compared to analyst estimates of $5.63 million. The company’s revenue was up 233.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($9.57) EPS. Equities research analysts anticipate that Intellia Therapeutics will post ($1.32) earnings per share for the current fiscal year.
In other Intellia Therapeutics news, Director Jean Francois Formela sold 21,132 shares of the company’s stock in a transaction on Friday, March 10th. The shares were sold at an average price of $13.91, for a total value of $293,946.12. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Institutional investors have recently added to or reduced their stakes in the stock. Neuberger Berman Group LLC raised its stake in Intellia Therapeutics by 1.3% in the third quarter. Neuberger Berman Group LLC now owns 78,486 shares of the company’s stock worth $1,336,000 after buying an additional 1,000 shares during the period. SG Americas Securities LLC raised its position in shares of Intellia Therapeutics by 53.1% in the third quarter. SG Americas Securities LLC now owns 26,815 shares of the company’s stock valued at $456,000 after buying an additional 9,306 shares during the last quarter. ClariVest Asset Management LLC acquired a new position in shares of Intellia Therapeutics during the third quarter valued at $159,000. Perceptive Advisors LLC acquired a new position in shares of Intellia Therapeutics during the fourth quarter valued at $192,000. Finally, ARK Investment Management LLC acquired a new position in shares of Intellia Therapeutics during the fourth quarter valued at $348,000.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.